



REPORTED SALES vs. PRIOR PERIOD (\$MM)

	SECOND QUARTER				
	2020	2019	% Change		
			Reported	Operational ⁽¹⁾	Currency
CONSUMER HEALTH SEGMENT ^(2,3)					
BABY CARE					
US	\$ 96	99	-3.5%	-3.5%	-
Intl	260	344	-24.3%	-16.6%	-7.7%
WW	356	443	-19.7%	-13.6%	-6.1%
ORAL CARE					
US	170	155	9.7%	9.7%	-
Intl	227	234	-2.8%	4.0%	-6.8%
WW	397	389	2.2%	6.3%	-4.1%
OTC					
US	627	484	29.6%	29.6%	-
Intl	522	580	-10.1%	-5.0%	-5.1%
WW	1,149	1,064	7.9%	10.7%	-2.8%
SKIN HEALTH / BEAUTY ⁽⁴⁾					
US	536	663	-19.2%	-19.2%	-
Intl	471	539	-12.5%	-8.2%	-4.3%
WW	1,007	1,202	-16.2%	-14.3%	-1.9%
WOMEN'S HEALTH					
US	3	3	-2.9%	-2.9%	-
Intl	199	250	-20.4%	-12.0%	-8.4%
WW	202	253	-20.1%	-11.8%	-8.3%
WOUND CARE / OTHER					
US	126	132	-4.7%	-4.7%	-
Intl	59	61	-2.4%	3.7%	-6.1%
WW	185	193	-4.0%	-2.1%	-1.9%
TOTAL CONSUMER HEALTH					
US	1,557	1,537	1.3%	1.3%	-
Intl	1,739	2,007	-13.4%	-7.4%	-6.0%
WW	\$ 3,296	3,544	-7.0%	-3.6%	-3.4%

REPORTED SALES vs. PRIOR PERIOD (\$MM)

	SIX MONTHS				
	2020	2019	% Change		
			Reported	Operational ⁽¹⁾	Currency
CONSUMER HEALTH SEGMENT ^(2,3)					
BABY CARE					
US	\$ 188	186	1.2%	1.2%	-
Intl	529	651	-18.7%	-12.6%	-6.1%
WW	717	837	-14.3%	-9.5%	-4.8%
ORAL CARE					
US	346	306	12.9%	12.9%	-
Intl	446	450	-0.8%	4.6%	-5.4%
WW	792	756	4.8%	8.0%	-3.2%
OTC					
US	1,316	991	32.8%	32.8%	-
Intl	1,181	1,160	1.8%	6.0%	-4.2%
WW	2,497	2,151	16.1%	18.3%	-2.2%
SKIN HEALTH / BEAUTY ⁽⁴⁾					
US	1,195	1,251	-4.5%	-4.5%	-
Intl	929	1,041	-10.7%	-7.4%	-3.3%
WW	2,124	2,292	-7.3%	-5.8%	-1.5%
WOMEN'S HEALTH					
US	7	6	14.3%	14.3%	-
Intl	427	472	-9.6%	-2.1%	-7.5%
WW	434	478	-9.3%	-1.9%	-7.4%
WOUND CARE / OTHER					
US	245	234	4.7%	4.7%	-
Intl	111	114	-1.9%	2.8%	-4.7%
WW	356	348	2.6%	4.1%	-1.5%
TOTAL CONSUMER HEALTH					
US	3,297	2,975	10.8%	10.8%	-
Intl	3,624	3,887	-6.8%	-1.9%	-4.9%
WW	\$ 6,921	6,862	0.9%	3.6%	-2.7%

See footnotes at end of schedule

PHARMACEUTICAL SEGMENT ^(2,5)	REPORTED SALES vs. PRIOR PERIOD (\$MM)					REPORTED SALES vs. PRIOR PERIOD (\$MM)				
	SECOND QUARTER					SIX MONTHS				
	2020	2019	% Change			2020	2019	% Change		
		Reported	Operational ⁽¹⁾	Currency			Reported	Operational ⁽¹⁾	Currency	
IMMUNOLOGY										
US	\$ 2,362	2,379	-0.7%	-0.7%	-	\$ 4,772	4,542	5.1%	5.1%	-
Intl	1,161	1,087	6.8%	11.0%	-4.2%	2,389	2,175	9.8%	13.7%	-3.9%
WW	3,523	3,466	1.6%	3.0%	-1.4%	7,161	6,717	6.6%	7.9%	-1.3%
REMICADE										
US	593	801	-25.8%	-25.8%	-	1,218	1,575	-22.7%	-22.7%	-
US Exports ⁽⁶⁾	133	62	*	*	-	243	138	75.7%	75.7%	-
Intl	208	244	-14.5%	-8.7%	-5.8%	464	496	-6.4%	-1.6%	-4.8%
WW	935	1,107	-15.5%	-14.2%	-1.3%	1,925	2,209	-12.9%	-11.8%	-1.1%
SIMPONI / SIMPONI ARIA										
US	256	281	-8.7%	-8.7%	-	528	544	-2.9%	-2.9%	-
Intl	289	282	2.6%	6.8%	-4.2%	547	543	0.8%	4.8%	-4.0%
WW	546	563	-3.0%	-0.9%	-2.1%	1,075	1,087	-1.1%	1.0%	-2.1%
STELARA										
US	1,138	1,058	7.5%	7.5%	-	2,355	1,940	21.4%	21.4%	-
Intl	558	499	11.9%	15.5%	-3.6%	1,161	1,022	13.6%	16.9%	-3.3%
WW	1,697	1,558	8.9%	10.1%	-1.2%	3,516	2,963	18.7%	19.8%	-1.1%
TREMFYA										
US	241	176	36.7%	36.7%	-	428	344	24.4%	24.4%	-
Intl	101	59	71.0%	73.4%	-2.4%	210	108	94.0%	97.1%	-3.1%
WW	342	235	45.4%	46.0%	-0.6%	638	452	41.1%	41.8%	-0.7%
OTHER IMMUNOLOGY										
US	-	-	-	-	-	-	-	-	-	-
Intl	3	3	11.8%	21.6%	-9.8%	6	6	2.7%	8.4%	-5.7%
WW	3	3	11.8%	21.6%	-9.8%	6	6	2.7%	8.4%	-5.7%
INFECTIOUS DISEASES										
US	416	387	7.4%	7.4%	-	852	744	14.5%	14.5%	-
Intl	463	475	-2.5%	2.6%	-5.1%	946	964	-1.8%	2.7%	-4.5%
WW	878	862	1.9%	4.7%	-2.8%	1,798	1,708	5.3%	7.8%	-2.5%
EDURANT / rilpivirine										
US	10	12	-14.0%	-14.0%	-	22	24	-6.9%	-6.9%	-
Intl	246	198	24.5%	27.7%	-3.2%	458	397	15.4%	18.4%	-3.0%
WW	256	210	22.2%	25.2%	-3.0%	480	421	14.1%	17.0%	-2.9%
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA										
US	379	344	10.5%	10.5%	-	775	659	17.7%	17.7%	-
Intl	130	191	-32.0%	-26.1%	-5.9%	314	399	-21.4%	-15.8%	-5.6%
WW	510	535	-4.7%	-2.6%	-2.1%	1,089	1,058	2.9%	5.0%	-2.1%
OTHER INFECTIOUS DISEASES										
US	25	31	-18.7%	-18.7%	-	54	61	-11.2%	-11.2%	-
Intl	87	86	1.0%	8.7%	-7.7%	174	168	3.8%	9.4%	-5.6%
WW	113	117	-4.2%	1.5%	-5.7%	229	229	-0.2%	3.9%	-4.1%

	REPORTED SALES vs. PRIOR PERIOD (\$MM)					REPORTED SALES vs. PRIOR PERIOD (\$MM)				
	SECOND QUARTER					SIX MONTHS				
	2020	2019	% Change			2020	2019	% Change		
		Reported	Operational ⁽¹⁾	Currency			Reported	Operational ⁽¹⁾	Currency	
NEUROSCIENCE										
US	778	664	17.4%	17.4%	-	1,526	1,387	10.1%	10.1%	-
Intl	809	875	-7.6%	-4.1%	-3.5%	1,719	1,780	-3.5%	-0.5%	-3.0%
WW	1,587	1,538	3.2%	5.2%	-2.0%	3,245	3,167	2.5%	4.1%	-1.6%
<u>CONCERTA / Methylphenidate</u>										
US	55	15	*	*	-	107	112	-4.2%	-4.2%	-
Intl	94	123	-23.0%	-20.2%	-2.8%	212	239	-11.0%	-8.6%	-2.4%
WW	149	137	8.7%	11.2%	-2.5%	320	351	-8.9%	-7.2%	-1.7%
<u>INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA</u>										
US	576	506	13.8%	13.8%	-	1,120	989	13.2%	13.2%	-
Intl	303	312	-2.8%	0.3%	-3.1%	642	619	3.7%	6.7%	-3.0%
WW	879	818	7.5%	8.6%	-1.1%	1,762	1,608	9.5%	10.7%	-1.2%
<u>RISPERDAL CONSTA</u>										
US	74	81	-9.3%	-9.3%	-	150	158	-4.9%	-4.9%	-
Intl	79	101	-21.2%	-18.1%	-3.1%	173	203	-14.9%	-11.9%	-3.0%
WW	153	182	-15.9%	-14.2%	-1.7%	323	361	-10.5%	-8.9%	-1.6%
<u>OTHER NEUROSCIENCE</u>										
US	75	62	21.5%	21.5%	-	150	128	16.8%	16.8%	-
Intl	331	340	-2.5%	1.7%	-4.2%	691	719	-3.9%	-0.8%	-3.1%
WW	406	401	1.2%	4.7%	-3.5%	841	847	-0.7%	1.8%	-2.5%
ONCOLOGY										
US	1,181	1,013	16.6%	16.6%	-	2,356	1,975	19.3%	19.3%	-
Intl	1,609	1,684	-4.4%	-0.9%	-3.5%	3,448	3,240	6.4%	9.9%	-3.5%
WW	2,791	2,697	3.5%	5.7%	-2.2%	5,804	5,215	11.3%	13.5%	-2.2%
<u>DARZALEX</u>										
US	492	369	32.9%	32.9%	-	955	721	32.3%	32.3%	-
Intl	409	405	1.2%	5.9%	-4.7%	883	682	29.6%	34.7%	-5.1%
WW	901	774	16.3%	18.8%	-2.5%	1,838	1,403	31.0%	33.5%	-2.5%
<u>ERLEADA</u>										
US	136	62	*	*	-	255	120	*	*	-
Intl	33	7	*	*	*	57	10	*	*	*
WW	170	69	*	*	*	313	130	*	*	*
<u>IMBRUVICA</u>										
US	447	367	21.5%	21.5%	-	879	716	22.6%	22.6%	-
Intl	502	463	8.3%	13.4%	-5.1%	1,101	898	22.6%	27.4%	-4.8%
WW	949	831	14.1%	17.0%	-2.9%	1,980	1,615	22.6%	25.3%	-2.7%
<u>VELCADE</u>										
US	-	-	-	-	-	-	-	-	-	-
Intl	98	224	-56.1%	-55.2%	-0.9%	206	487	-57.7%	-56.9%	-0.8%
WW	98	224	-56.1%	-55.2%	-0.9%	206	487	-57.7%	-56.9%	-0.8%
<u>ZYTIGA / abiraterone acetate</u>										
US	87	198	-55.6%	-55.6%	-	226	383	-40.9%	-40.9%	-
Intl	480	500	-3.9%	-2.0%	-1.9%	1,032	994	3.8%	6.1%	-2.3%
WW	568	698	-18.6%	-17.2%	-1.4%	1,258	1,377	-8.6%	-7.0%	-1.6%
<u>OTHER ONCOLOGY</u>										
US	20	16	22.9%	22.9%	-	42	34	21.4%	21.4%	-
Intl	87	85	2.2%	5.9%	-3.7%	169	169	-0.3%	3.3%	-3.6%
WW	106	101	5.5%	8.6%	-3.1%	210	203	3.4%	6.3%	-2.9%
PULMONARY HYPERTENSION										
US	545	439	24.2%	24.2%	-	1,031	869	18.7%	18.7%	-
Intl	243	251	-3.3%	-1.0%	-2.3%	503	477	5.3%	7.9%	-2.6%
WW	789	690	14.2%	15.0%	-0.8%	1,534	1,346	13.9%	14.9%	-1.0%
<u>OPSUMIT</u>										
US	256	203	26.1%	26.1%	-	485	375	29.3%	29.3%	-
Intl	150	146	3.0%	5.7%	-2.7%	310	279	11.2%	14.1%	-2.9%
WW	406	348	16.5%	17.6%	-1.1%	795	654	21.6%	22.8%	-1.2%
<u>UPTRAVI</u>										
US	254	175	44.5%	44.5%	-	466	351	32.6%	32.6%	-
Intl	28	28	4.0%	7.3%	-3.3%	66	50	33.6%	37.6%	-4.0%
WW	282	203	39.0%	39.5%	-0.5%	532	401	32.7%	33.2%	-0.5%
<u>OTHER PULMONARY HYPERTENSION</u>										
US	37	61	-40.2%	-40.2%	-	81	143	-43.5%	-43.5%	-
Intl	64	78	-17.6%	-16.4%	-1.2%	126	149	-15.1%	-13.7%	-1.4%
WW	101	140	-27.5%	-26.9%	-0.6%	207	292	-29.0%	-28.3%	-0.7%
CARDIOVASCULAR / METABOLISM / OTHER										
US	837	902	-7.2%	-7.2%	-	1,643	1,849	-11.1%	-11.1%	-
Intl	347	373	-7.0%	-2.4%	-4.6%	701	771	-9.1%	-5.6%	-3.5%
WW	1,184	1,275	-7.1%	-5.8%	-1.3%	2,344	2,620	-10.5%	-9.5%	-1.0%
<u>XARELTO</u>										
US	559	549	1.7%	1.7%	-	1,086	1,091	-0.5%	-0.5%	-
Intl	-	-	-	-	-	-	-	-	-	-
WW	559	549	1.7%	1.7%	-	1,086	1,091	-0.5%	-0.5%	-
<u>INVOKANA / INVOKAMET</u>										
US	132	132	-0.8%	-0.8%	-	249	286	-13.0%	-13.0%	-
Intl	47	43	9.1%	14.8%	-5.7%	105	92	14.1%	18.1%	-4.0%
WW	179	177	1.6%	3.1%	-1.5%	354	379	-6.4%	-5.5%	-0.9%
<u>PROCRIT / EPREX</u>										
US	70	113	-38.3%	-38.3%	-	146	261	-44.1%	-44.1%	-
Intl	66	70	-5.0%	-2.3%	-2.7%	145	148	-2.2%	-0.1%	-2.1%
WW	136	183	-25.6%	-24.6%	-1.0%	291	409	-28.9%	-28.2%	-0.7%
<u>OTHER</u>										
US	78	107	-27.7%	-27.7%	-	163	211	-22.9%	-22.9%	-
Intl	234	260	-10.2%	-5.3%	-4.9%	451	531	-15.0%	-11.3%	-3.7%
WW	312	368	-15.3%	-11.8%	-3.5%	614	742	-17.3%	-14.6%	-2.7%
TOTAL PHARMACEUTICAL										
US	6,120	5,783	5.8%	5.8%	-	12,181	11,365	7.2%	7.2%	-
Intl	4,632	4,746	-2.4%	1.4%	-3.8%	9,705	9,408	3.2%	6.7%	-3.5%
WW	\$ 10,752	\$ 10,529	2.1%	3.9%	-1.8%	\$ 21,886	\$ 20,773	5.4%	7.0%	-1.6%

See footnotes at end of schedule

	REPORTED SALES vs. PRIOR PERIOD (\$MM)					REPORTED SALES vs. PRIOR PERIOD (\$MM)				
	SECOND QUARTER					SIX MONTHS				
	2020	2019	Reported	% Change Operational ⁽¹⁾	Currency	2020	2019	Reported	% Change Operational ⁽¹⁾	Currency
MEDICAL DEVICES SEGMENT ^(2,5)										
INTERVENTIONAL SOLUTIONS										
US	255	366	-30.5%	-30.5%	-	620	709	-12.6%	-12.6%	-
Intl	335	385	-12.8%	-10.9%	-1.9%	697	774	-9.9%	-8.0%	-1.9%
WW	590	750	-21.5%	-20.5%	-1.0%	1,317	1,482	-11.2%	-10.2%	-1.0%
ORTHOPAEDICS										
US	869	1,331	-34.7%	-34.7%	-	2,119	2,649	-20.0%	-20.0%	-
Intl	583	894	-34.8%	-32.6%	-2.2%	1,371	1,779	-22.9%	-20.6%	-2.3%
WW	1,451	2,224	-34.7%	-33.9%	-0.8%	3,489	4,428	-21.2%	-20.3%	-0.9%
HIPS										
US	137	216	-36.5%	-36.5%	-	343	429	-20.1%	-20.1%	-
Intl	88	147	-39.8%	-37.3%	-2.5%	220	295	-25.4%	-22.8%	-2.6%
WW	226	364	-37.8%	-36.8%	-1.0%	563	725	-22.3%	-21.2%	-1.1%
KNEES										
US	108	218	-50.5%	-50.5%	-	322	441	-27.1%	-27.1%	-
Intl	66	153	-56.8%	-55.3%	-1.5%	196	299	-34.6%	-32.7%	-1.9%
WW	174	372	-53.1%	-52.5%	-0.6%	517	741	-30.1%	-29.3%	-0.8%
TRAUMA										
US	354	407	-12.9%	-12.9%	-	761	824	-7.6%	-7.6%	-
Intl	198	265	-25.2%	-22.6%	-2.6%	445	533	-16.5%	-13.9%	-2.6%
WW	553	672	-17.8%	-16.7%	-1.1%	1,207	1,357	-11.1%	-10.0%	-1.1%
SPINE, SPORTS & OTHER ⁽⁷⁾										
US	270	490	-45.0%	-45.0%	-	693	955	-27.4%	-27.4%	-
Intl	230	328	-29.9%	-27.9%	-2.0%	510	651	-21.7%	-19.6%	-2.1%
WW	499	818	-39.0%	-38.2%	-0.8%	1,202	1,606	-25.1%	-24.3%	-0.8%
SURGERY										
US	490	926	-47.0%	-47.0%	-	1,334	1,927	-30.8%	-30.8%	-
Intl	1,060	1,427	-25.7%	-22.6%	-3.1%	2,317	2,821	-17.9%	-14.8%	-3.1%
WW	1,551	2,353	-34.1%	-32.2%	-1.9%	3,651	4,748	-23.1%	-21.3%	-1.8%
ADVANCED										
US	277	396	-30.0%	-30.0%	-	658	800	-17.7%	-17.7%	-
Intl	498	633	-21.2%	-18.4%	-2.8%	1,065	1,209	-11.9%	-8.9%	-3.0%
WW	775	1,029	-24.6%	-22.9%	-1.7%	1,723	2,009	-14.2%	-12.4%	-1.8%
GENERAL										
US	213	530	-59.8%	-59.8%	-	676	1,127	-40.0%	-40.0%	-
Intl	562	794	-29.2%	-26.0%	-3.2%	1,252	1,612	-22.4%	-19.2%	-3.2%
WW	775	1,325	-41.5%	-39.5%	-2.0%	1,928	2,739	-29.6%	-27.8%	-1.8%
VISION										
US	248	461	-46.1%	-46.1%	-	687	907	-24.2%	-24.2%	-
Intl	447	701	-36.1%	-34.8%	-1.3%	1,075	1,383	-22.3%	-20.8%	-1.5%
WW	695	1,161	-40.1%	-39.3%	-0.8%	1,762	2,290	-23.0%	-22.2%	-0.8%
CONTACT LENSES / OTHER										
US	203	333	-39.0%	-39.0%	-	549	654	-16.1%	-16.1%	-
Intl	352	509	-30.9%	-29.6%	-1.3%	819	1,011	-19.0%	-17.6%	-1.4%
WW	554	842	-34.1%	-33.3%	-0.8%	1,368	1,666	-17.9%	-17.0%	-0.9%
SURGICAL										
US	45	128	-64.6%	-64.6%	-	138	253	-45.3%	-45.3%	-
Intl	96	191	-49.9%	-48.8%	-1.1%	256	371	-31.0%	-29.6%	-1.4%
WW	141	319	-55.8%	-55.2%	-0.6%	394	624	-36.8%	-36.0%	-0.8%
TOTAL MEDICAL DEVICES										
US	1,862	3,083	-39.6%	-39.6%	-	4,760	6,192	-23.1%	-23.1%	-
Intl	2,426	3,406	-28.8%	-26.4%	-2.4%	5,460	6,756	-19.2%	-16.8%	-2.4%
WW	\$ 4,288	\$ 6,489	-33.9%	-32.7%	-1.2%	\$ 10,220	\$ 12,948	-21.1%	-19.8%	-1.3%

Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

* Percentage greater than 100% or not meaningful

(1) Operational growth excludes the effect of translational currency

(2) Unaudited

(3) Previously referred to as Consumer

(4) Previously referred to as Beauty

(5) Certain prior year amounts have been reclassified to conform to current year product disclosures

(6) Reported as U.S. sales

(7) Previously referred to as Spine & Other